Developer docs
API playgroundTry for free, no card

Search company profiles

Healius Ltd

Full company profile

uuid002r5xk

Namestring
Healius Ltd
Legal namestring
Healius Ltd
Websiteurl
healius.com.au
Company typeenum
Public
Founded yearint
1993
Descriptiontext

Healius Ltd (ASX: HLS) is one of Australia's largest specialty diagnostic and pathology providers, operating a national network of 2,063 approved collection centres and 95 laboratories through a portfolio of regional brands — Laverty Pathology (NSW/ACT), Dorevitch Pathology (VIC), QML Pathology (QLD), Abbott Pathology (SA), Western Diagnostic Pathology (WA/NT), and TML Pathology (TAS) — alongside specialist brands for dermatopathology (IQ Pathology, Kossard Dermatopathologists), genomics (Genomic Diagnostics), gastroenterology (Gastrolab), clinical trial bioanalysis (Agilex Biolabs), and veterinary pathology (Vetnostics). The company processes approximately one in three pathology samples taken in Australia and employs 8,000+ people across the country.

The core technology stack is built around Laboratory Information Systems (LIS) that manage pathology data across the laboratory network, augmented by AI tools ('AI co-workers') used to support pathologists in result interpretation and clinical decision support, plus a national pharmacogenomics (PGx) testing capability within the Genomic Diagnostics brand. Distribution is centred on the owned collection-centre network, with patients referred by general practitioners and specialists who account for the bulk of pathology demand.

Revenue is generated primarily through Medicare Australia bulk-billing rebates for routine pathology services (a stream subject to multi-decade stagnation in rebate indexation), supplemented by direct commercial pathology contracts with employers and government clients — including an approximately A$60 million, five-year Australian Defence Force contract — plus revenue from specialized testing partnerships such as the BCAL Diagnostics Avantect cancer screening distribution agreement. 1H FY2026 revenue was A$688.1 million (+3.8% YoY), with underlying EBIT of A$7.9 million, A$18 million in annualized cost savings, a net loss of A$30.4 million, and genomics segment revenue growing 21.6% over the period.

Short descriptiontext

Healius Ltd is one of Australia's largest pathology providers, operating 2,000+ collection centres and 95 laboratories under regional brands and processing roughly one in three pathology samples nationally for patients, GPs, and government clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pathology services, diagnostic testing, laboratory services, medical diagnostics, genetic testing
Industry1 code
1Point-of-Care & Decentralized Trial Testing Services
CodeHLAGAEAKPrimaryYes
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Pathology Diagnostic Services
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Medicare Pathology Rebates
TypeSubscription Recurring
Description

Bulk-billed pathology services funded through Medicare Australia rebates. The company faces chronic underfunding of Medicare pathology rebates spanning approximately 24 years without inflation indexation.

stocksdownunder.com
2Commercial Pathology Services
TypeTransaction Fee
Description

Direct pathology testing services to commercial clients including employers, government departments, and corporate customers

healius.com.au
3Government Contracts
TypeManaged Services
Description

Contracts with government entities including Australian Defence Force worth approximately $60 million over 5 years

seekingalpha.com
4Specialized Testing Partnerships
TypeTransaction Fee
Description

Revenue from distributing specialized tests through partnership arrangements with companies like BCAL Diagnostics

smallcaps.com.au
5Veterinary Pathology Services
TypeTransaction Fee
Description

Vetnostics brand provides veterinary pathology laboratory services through Specialist Veterinary Services Pty Ltd

healius.com.au
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Pricing details1 tier
1Standard bulk-billed pathology services through Medicare
ModelSubscriptionBilling cadencePer service
Notes

Most pathology services are bulk-billed through Medicare Australia, with patients generally not paying out-of-pocket costs

stocksdownunder.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 2 records shown
1Agilex Biolabs
Description

Bioanalysis and sample analysis services with 25 years of experience in performing regulated bio analysis.

healius.com.au
+1 more record
Core offering1 text field

Healius operates a national pathology and diagnostic services network providing specialty diagnostic testing to consumers and referring practitioners across Australia. Core offerings include clinical pathology (blood tests, tissue diagnostics), genetic and pharmacogenomic testing, dermatopathology, functional gastroenterology testing, veterinary pathology, and bioanalytical services for clinical trials, delivered through 2,000+ collection centres and 95 laboratories under multiple regional brands. Revenue is generated primarily through Medicare bulk-billed rebates, commercial contracts with employers and government entities, and distribution partnerships for specialised third-party tests.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 70% of medical decisions involve pathology
+2 more records
Product overview1 text field

Healius Ltd operates as a multi-brand pathology laboratory network providing specialty diagnostic services across Australia. The portfolio consists of a unified pathology network (Healius Pathology Network) with 12 regional sub-brands covering all Australian states and territories. The main brands include Laverty Pathology (NSW/ACT), Dorevitch Pathology (VIC), QML Pathology (QLD), Abbott Pathology (SA), Western Diagnostic Pathology (WA/NT), and TML Pathology (TAS), alongside specialist brands for dermatopathology (IQ Pathology, Kossard Dermatopathologists), genomics (Genomic Diagnostics), gastroenterology (Gastrolab), clinical trials (Agilex Biolabs), and veterinary pathology (Vetnostics). The network operates from 95 laboratories and over 2,000 collection centres, processing approximately one in three pathology samples in Australia.

Product and service14 records
1Healius Pathology Network
CategoryPathology diagnostic services
2Laverty Pathology
CategoryPathology diagnostic services
3Dorevitch Pathology
CategoryPathology diagnostic services
4QML Pathology
CategoryPathology diagnostic services
5Abbott Pathology
CategoryPathology diagnostic services
6Western Diagnostic Pathology (WDP)
CategoryPathology diagnostic services
7TML Pathology
CategoryPathology diagnostic services
8Genomic Diagnostics
CategoryGenetic and genomic testing
9Agilex Biolabs
CategoryClinical trial bioanalytical services
10IQ Pathology
CategoryDermatopathology services
11Kossard Dermatopathologists
CategoryDermatopathology services
12Gastrolab
CategoryGastroenterology diagnostic services
13Vetnostics
CategoryVeterinary pathology services
14Avantect Early Detection Blood Tests (BCAL partnership distribution)
CategoryCancer early detection testing
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-26
Description

BCAL Diagnostics is expanding commercial rollout of its Avantect early detection blood tests for pancreatic and ovarian cancers through a new partnership with Healius, making tests available through pathology collection centres across Australia. Tests are priced at $1,495 per test or $1,995 for combined testing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Healius Pathology Network announced a strategic partnership with RACGP to enhance GP learning and professional development in pathology testing and interpretation.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-08-30
Description

Healius announced partnership in precision medicine for timely detection of Alzheimer's disease with C2N Diagnostics.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-05-11
Description

Healius announced collaboration with Minderoo Foundation for COVID-19 testing during the pandemic.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-10-11
Description

Primary HealthCare (now Healius) joined Global Diagnostics Network as a Founding Member, providing access to global diagnostic expertise and network.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Australian Clinical Labs is one of Australia's largest pathology providers and Healius' closest direct competitor. ACL attempted to acquire Healius for A$1.58bn in 2023 before the deal was blocked by the ACCC, highlighting their directly competitive positioning.

TypeDirect peer
Description

Melbourne Pathology is a major Victorian pathology provider offering comprehensive diagnostic services. It directly competes with Healius' Dorevitch Pathology in the Victorian market.

TypeBroad incumbent
Description

Quest Diagnostics is one of the largest clinical laboratory services companies globally. It serves as a broad incumbent comparable to Healius in diagnostic testing services, advanced genomics, and employer health services.

TypeDirect peer
Description

Healthscope operates hospital and pathology services across Australia, including Healthscope Pathology. It competes directly with Healius in providing pathology services to hospitals, GPs, and specialists nationwide.

TypeEmerging player
Description

4Cyte Pathology is an Australian pathology provider offering diagnostic services through a network of collection centres and laboratories, competing with Healius for GP referrals and patient volume in selected markets.

TypeBroad incumbent
Description

SYNLAB is Europe's leading medical diagnostic services provider offering clinical laboratory testing across multiple countries. Comparable to Healius in core pathology services and specialized diagnostics including genomics.

TypeDirect peer
Description

Douglass Hanly Moir is a subsidiary of Sonic Healthcare operating in NSW, providing pathology services through laboratories and collection centres. It competes directly with Healius' Laverty Pathology in overlapping geographies.

TypeRegional player
Description

Awanui Pathology is a major New Zealand-based pathology laboratory network. It is comparable to Healius in business model and services but operates primarily across New Zealand rather than Australia.

TypeBroad incumbent
Description

LabCorp is a leading global clinical laboratory services company. While primarily US-based, it represents the global benchmark for clinical laboratory business models and is comparable in service offerings to Healius' pathology operations.

TypeDirect peer
Description

Sonic Healthcare is the largest pathology/diagnostics provider in Australia and globally, operating laboratories and collection centres across multiple countries. It is Healius' primary direct competitor in Australian pathology with overlapping service offerings and customer segments.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Healius Ltd

Pathology Diagnostic Serviceshealius.com.au

Healius Ltd is one of Australia's largest pathology providers, operating 2,000+ collection centres and 95 laboratories under regional brands and processing roughly one in three pathology samples nationally for patients, GPs, and government clients.

What Healius Ltd does

Healius Ltd (ASX: HLS) is one of Australia's largest specialty diagnostic and pathology providers, operating a national network of 2,063 approved collection centres and 95 laboratories through a portfolio of regional brands — Laverty Pathology (NSW/ACT), Dorevitch Pathology (VIC), QML Pathology (QLD), Abbott Pathology (SA), Western Diagnostic Pathology (WA/NT), and TML Pathology (TAS) — alongside specialist brands for dermatopathology (IQ Pathology, Kossard Dermatopathologists), genomics (Genomic Diagnostics), gastroenterology (Gastrolab), clinical trial bioanalysis (Agilex Biolabs), and veterinary pathology (Vetnostics). The company processes approximately one in three pathology samples taken in Australia and employs 8,000+ people across the country.

The core technology stack is built around Laboratory Information Systems (LIS) that manage pathology data across the laboratory network, augmented by AI tools ('AI co-workers') used to support pathologists in result interpretation and clinical decision support, plus a national pharmacogenomics (PGx) testing capability within the Genomic Diagnostics brand. Distribution is centred on the owned collection-centre network, with patients referred by general practitioners and specialists who account for the bulk of pathology demand.

Revenue is generated primarily through Medicare Australia bulk-billing rebates for routine pathology services (a stream subject to multi-decade stagnation in rebate indexation), supplemented by direct commercial pathology contracts with employers and government clients — including an approximately A$60 million, five-year Australian Defence Force contract — plus revenue from specialized testing partnerships such as the BCAL Diagnostics Avantect cancer screening distribution agreement. 1H FY2026 revenue was A$688.1 million (+3.8% YoY), with underlying EBIT of A$7.9 million, A$18 million in annualized cost savings, a net loss of A$30.4 million, and genomics segment revenue growing 21.6% over the period.

Healius Ltd firmographics

Firmographics
Name
Healius Ltd
Legal name
Healius Ltd
Website
https://healius.com.au
Company type
Public
Founded year
1993
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Healius Ltd is one of Australia's largest pathology providers, operating 2,000+ collection centres and 95 laboratories under regional brands and processing roughly one in three pathology samples nationally for patients, GPs, and government clients.
Ownership category
akta.pro rank

Healius Ltd industry classification

Industry
Product category
Pathology Diagnostic Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071)
akta.pro primary industry
Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)

Keywords

  • Pathology services
  • Diagnostic testing
  • Laboratory services
  • Medical diagnostics
  • Genetic testing

Where Healius Ltd is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

Healius Ltd business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Medicare Pathology Rebates: Bulk-billed pathology services funded through Medicare Australia rebates. The company faces chronic underfunding of Medicare pathology rebates spanning approximately 24 years without inflation indexation.
  2. Commercial Pathology Services: Direct pathology testing services to commercial clients including employers, government departments, and corporate customers
  3. Government Contracts: Contracts with government entities including Australian Defence Force worth approximately $60 million over 5 years
  4. Specialized Testing Partnerships: Revenue from distributing specialized tests through partnership arrangements with companies like BCAL Diagnostics
  5. Veterinary Pathology Services: Vetnostics brand provides veterinary pathology laboratory services through Specialist Veterinary Services Pty Ltd

Pricing tiers

ModelBillingPrice
SubscriptionPer serviceStandard bulk-billed pathology services through Medicare

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Healius Ltd product offering

Product offering

Core offering

Healius operates a national pathology and diagnostic services network providing specialty diagnostic testing to consumers and referring practitioners across Australia. Core offerings include clinical pathology (blood tests, tissue diagnostics), genetic and pharmacogenomic testing, dermatopathology, functional gastroenterology testing, veterinary pathology, and bioanalytical services for clinical trials, delivered through 2,000+ collection centres and 95 laboratories under multiple regional brands. Revenue is generated primarily through Medicare bulk-billed rebates, commercial contracts with employers and government entities, and distribution partnerships for specialised third-party tests.

Product overview

Healius Ltd operates as a multi-brand pathology laboratory network providing specialty diagnostic services across Australia. The portfolio consists of a unified pathology network (Healius Pathology Network) with 12 regional sub-brands covering all Australian states and territories. The main brands include Laverty Pathology (NSW/ACT), Dorevitch Pathology (VIC), QML Pathology (QLD), Abbott Pathology (SA), Western Diagnostic Pathology (WA/NT), and TML Pathology (TAS), alongside specialist brands for dermatopathology (IQ Pathology, Kossard Dermatopathologists), genomics (Genomic Diagnostics), gastroenterology (Gastrolab), clinical trials (Agilex Biolabs), and veterinary pathology (Vetnostics). The network operates from 95 laboratories and over 2,000 collection centres, processing approximately one in three pathology samples in Australia.

Differentiator

Problem solved

Functional benefit

Brands

  • Agilex Biolabs: Bioanalysis and sample analysis services with 25 years of experience in performing regulated bio analysis.
  • Genomic Diagnostics

Products and services

  • Healius Pathology Network
  • Laverty Pathology
  • Dorevitch Pathology
  • QML Pathology
  • Abbott Pathology
  • Western Diagnostic Pathology (WDP)
  • TML Pathology
  • Genomic Diagnostics
  • Agilex Biolabs
  • IQ Pathology
  • Kossard Dermatopathologists
  • Gastrolab
  • Vetnostics
  • Avantect Early Detection Blood Tests (BCAL partnership distribution)

Quantifiable outcome

  • 70% of medical decisions involve pathology
  • +2 more outcomes

Companies that use Healius Ltd

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Healius Ltd technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Healius Ltd partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • BCAL DiagnosticscoreStrategic or Co-development Partner · 26 March 2026BCAL Diagnostics is expanding commercial rollout of its Avantect early detection blood tests for pancreatic and ovarian cancers through a new partnership with Healius, making tests available through pathology collection centres across Australia. Tests are priced at $1,495 per test or $1,995 for combined testing.
  • RACGP (Royal Australian College of General Practitioners)coreStrategic or Co-development Partner · 17 March 2026Healius Pathology Network announced a strategic partnership with RACGP to enhance GP learning and professional development in pathology testing and interpretation.
  • C2N DiagnosticsminorStrategic or Co-development Partner · 30 August 2022Healius announced partnership in precision medicine for timely detection of Alzheimer's disease with C2N Diagnostics.
  • Minderoo FoundationminorStrategic or Co-development Partner · 11 May 2020Healius announced collaboration with Minderoo Foundation for COVID-19 testing during the pandemic.
  • Global Diagnostics Network (GDN)minorStrategic or Co-development Partner · 11 October 2018Primary HealthCare (now Healius) joined Global Diagnostics Network as a Founding Member, providing access to global diagnostic expertise and network.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Healius Ltd competitors and assessment

Company assessment

Direct peers

  • Australian Clinical Labs: Australian Clinical Labs is one of Australia's largest pathology providers and Healius' closest direct competitor. ACL attempted to acquire Healius for A$1.58bn in 2023 before the deal was blocked by the ACCC, highlighting their directly competitive positioning.
  • Melbourne Pathology: Melbourne Pathology is a major Victorian pathology provider offering comprehensive diagnostic services. It directly competes with Healius' Dorevitch Pathology in the Victorian market.
  • Healthscope Pathology: Healthscope operates hospital and pathology services across Australia, including Healthscope Pathology. It competes directly with Healius in providing pathology services to hospitals, GPs, and specialists nationwide.
  • Douglass Hanly Moir Pathology: Douglass Hanly Moir is a subsidiary of Sonic Healthcare operating in NSW, providing pathology services through laboratories and collection centres. It competes directly with Healius' Laverty Pathology in overlapping geographies.
  • Sonic Healthcare: Sonic Healthcare is the largest pathology/diagnostics provider in Australia and globally, operating laboratories and collection centres across multiple countries. It is Healius' primary direct competitor in Australian pathology with overlapping service offerings and customer segments.

Broad incumbents

  • Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory services companies globally. It serves as a broad incumbent comparable to Healius in diagnostic testing services, advanced genomics, and employer health services.
  • SYNLAB Group: SYNLAB is Europe's leading medical diagnostic services provider offering clinical laboratory testing across multiple countries. Comparable to Healius in core pathology services and specialized diagnostics including genomics.
  • LabCorp: LabCorp is a leading global clinical laboratory services company. While primarily US-based, it represents the global benchmark for clinical laboratory business models and is comparable in service offerings to Healius' pathology operations.

Emerging players

  • 4Cyte Pathology: 4Cyte Pathology is an Australian pathology provider offering diagnostic services through a network of collection centres and laboratories, competing with Healius for GP referrals and patient volume in selected markets.

Regional players

  • Awanui Pathology: Awanui Pathology is a major New Zealand-based pathology laboratory network. It is comparable to Healius in business model and services but operates primarily across New Zealand rather than Australia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Healius Ltd compliance and trust

Trust signal

Compliance4 records

Healius Ltd financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Healius Ltd leadership team

Management profile

Number of profiles

Profiles17 records

Healius Ltd subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Healius Ltd funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Healius Ltd M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Healius Ltd

What does Healius Ltd do?

Healius operates a national pathology and diagnostic services network providing specialty diagnostic testing to consumers and referring practitioners across Australia. Core offerings include clinical pathology (blood tests, tissue diagnostics), genetic and pharmacogenomic testing, dermatopathology, functional gastroenterology testing, veterinary pathology, and bioanalytical services for clinical trials, delivered through 2,000+ collection centres and 95 laboratories under multiple regional brands. Revenue is generated primarily through Medicare bulk-billed rebates, commercial contracts with employers and government entities, and distribution partnerships for specialised third-party tests.

Is Healius Ltd a public or private company?

Healius Ltd is a public company. It is classified as public and is currently operating.

When was Healius Ltd founded?

Healius Ltd was founded in 1993. It employs 5,001 to 10,000 people.

Where is Healius Ltd based?

Healius Ltd is headquartered in Sydney, Australia, in the Oceania region.

How does Healius Ltd make money?

Five revenue lines are on record. Medicare Pathology Rebates are the primary driver. The others are commercial Pathology Services, government Contracts, specialized Testing Partnerships and veterinary Pathology Services.

Who are Healius Ltd's main competitors?

Direct peers on record are Australian Clinical Labs, Melbourne Pathology, Healthscope Pathology, Douglass Hanly Moir Pathology and Sonic Healthcare. Broad incumbents are Quest Diagnostics, SYNLAB Group and LabCorp. 4Cyte Pathology is listed as an emerging player. Awanui Pathology is listed as a regional player.

Does Healius Ltd have an API?

No public API is recorded for Healius Ltd.

What industry is Healius Ltd in?

Healius Ltd's product category is Pathology Diagnostic Services. Its primary akta.pro industry code is HLAGAEAK, Point-of-Care & Decentralized Trial Testing Services. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmaTimesNovotech to acquire Agilex BiolabsNovotech agreed to acquire Agilex Biolabs, an Adelaide-based bioanalytical lab, from a Healius subsidiary. The deal adds Australian bioanalytical expertise to Novotech's Asia network and is subject to regulatory clearances. Novotech partners with over 5,000 trial sites.Pulse 2.0Novotech To Acquire Agilex Biolabs From Healius To Expand Australian Bioanalytical ServicesNovotech agreed to acquire Agilex Biolabs from Healius to expand its Australian bioanalytical laboratory services. The deal will add Agilex's Adelaide operations to Novotech's Asia-Pacific network, with financial terms undisclosed. Completion is subject to regulatory clearances, with no closing date set.The future of tradingAustralia's Healius rises on sale of unit Agilex Biolabs to Novotech HealthHealius shares rose 18.1% to A$0.425 after agreeing to sell its unit Agilex Biolabs to Novotech Health's subsidiary for A$160 million. The deal expects cash proceeds of A$155 million after costs, and the company said the disposal would unlock shareholder value and support focus on its core Pathology business.YahooHealius Ltd (ASX:HLS) (FY 2026) Earnings Call Highlights: EBIT Surges 76% to A$30. ...Healius Ltd reported a significant surge in Group Underlying EBIT to A$30.2 million for FY 2026, driven by disciplined cost control and improved revenue mix despite recording a large non-cash goodwill impairment of A$332 million. The company achieved A$24.4 million in annualized corporate cost savings through workforce reductions and digital transformation, while its Agilex Biolabs division saw strong growth in clinical trials revenue.AInvestHealius FY adjusted net income AUD -13.2 millionHealius Limited reported an adjusted net income loss of AUD 13.2 million for the fiscal year, continuing to struggle with high debt levels totaling AUD 911.8 million despite generating strong operating cash flow. The company faces structural challenges in its pathology and diagnostic imaging segments due to intense competition and government-controlled reimbursement schedules. Analysts remain cautious regarding Healius's ability to execute a turnaround, with price targets reflecting uncertainty about shareholder value recovery.The Sydney Morning HeraldProteomics taps Healius network for national diagnostics rolloutProteomics International Laboratories' shares rose up to 50% to 22.5 cents after it signed a three-year national distribution deal with Healius for its Promarker portfolio. The agreement gives Proteomics access to Healius' 2,000+ collection centres, with a phased rollout expected later this financial year.BloombergAustralia’s Healius Sells Lumus Imaging to Affinity Equity for $657 Million - BloombergHealius Ltd. agreed to sell its Lumus imaging unit to Affinity Equity Partners for A$965 million ($657 million). The sale, a 25.4 times full-year EBITDA multiple, will yield over A$800 million in net proceeds after adjustments and costs.ProactiveinvestorsCipherpoint drives commercial growth with $750,000 capital raiseCipherpoint Ltd raised $750,000 through a share placement with sophisticated and professional investors to fund its commercial growth strategy. The company intends to use these funds to ramp up resources for key projects following recent customer wins, including contracts with Lend Lease Retirement Living and Healius.Business Wire BlogC2N Diagnostics and Healius Ltd Announce Partnership to Bring PrecivityAD™ and Related Brain Health Biomarkers to Patients in AustraliaC2N Diagnostics and Healius announced a partnership to bring the PrecivityAD blood test and related brain health biomarkers to Australia. Healius will use its ~2,000 patient collection centers to collect samples for analysis at C2N's St. Louis lab. The companies expect further announcements on service access.